Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER100 in isolated systolic hypertension (randomized double-blind cross-over)
2013-001227-40Phase 2Completed
- Sponsor
- Serodus
- Start
- Jul 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SER-100 in isolated systolic hypertension (ISH) (2 arms), sponsored by Serodus. Primary endpoint: Adverse events. Started Jul 2013; status: completed.
02
Drugs
SER-100
03
Conditions
isolated systolic hypertension (ISH)
Beyond the preview
Go deeper on 2013-001227-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001227-40.